Nelson Tamala
Family Health · Chicago, ILNPI 1043762453
Payments from drug & device makers
Across 135 payments — averaging $33.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$504
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$385
- Otsuka America Pharmaceutical, Inc.$271
- Johnson & Johnson$252
- plus $314 from 4 others
What the payments were for
- Food & beverage$4,46998%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 46 | $1,594 |
| Neurocrine Biosciences, Inc. | 49 | $1,259 |
| Alkermes, Inc. | 12 | $504 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $385 |
| Otsuka America Pharmaceutical, Inc. | 4 | $271 |
| Johnson & Johnson | 7 | $252 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Acadia Pharmaceuticals Inc | 6 | $113 |
| Lundbeck LLC | 3 | $54 |
| Indivior Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$468
- Austedo XR$355
- CAPLYTA$344
- REXULTI$232
- AUSTEDO$223
- UZEDY$124
- COBENFY$122
- INVEGA SUSTENNA$116
How this compares
Too few family health providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 103 | $730,433 |
| Austedo XrDeutetrabenazine | 24 | $151,533 |
| Invega SustennaPaliperidone Palmitate | 21 | $65,189 |
| Chlorpromazine Hcl | 95 | $36,983 |
| Quetiapine Fumarate | 635 | $16,942 |
| Divalproex Sodium | 519 | $14,923 |
| Fluphenazine Hcl | 109 | $12,828 |
| RexultiBrexpiprazole | 15 | $12,757 |
| Clozapine | 182 | $12,068 |
| Olanzapine | 351 | $11,447 |
| Haloperidol | 279 | $10,711 |
| NamzaricMemantine Hcl/Donepezil Hcl | 54 | $8,468 |
| Fluphenazine Decanoate | 51 | $8,138 |
| Risperidone | 366 | $6,998 |
| Memantine Hcl | 130 | $4,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,259 | $730,433103 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,594 | $151,53324 claims |
| Johnson & JohnsonInvega Sustenna | $252 | $65,18921 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $271 | $12,75715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other family health in Chicago
- Emily BerwaldChicago$950
- Yolanda SankeyChicago$365
- Kristhine NagueNorthbrook$3K
- Penny FrickeSpringfield$141
- Shanakay HaughtonDowners Grove$110
- Laura BarnesElmhurst$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.